ARYx Therapeutics, Inc. (ARYX)
0.0000
0.00 (0.00%)
USD |
OTCM |
Feb 20, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 0.00 |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 0.00% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | -- |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 100.00% |
Profile
| ARYx Therapeutics, Inc. discovers and develops drugs for large, chronic disease markets. Its products include Naronapride, a proprietary serotonin type 4 (5HT4) for the treatment of multiple gastrointestinal disorders, Budiodarone, a proprietary compound in Phase 2 development for the treatment of atrial fibrillation, Tecarfarin, a novel compound for oral anti-coagulation therapy, and ATI-9242, a typical antipsychotic for the treatment of schizophrenia and other psychiatric disorders. The company was founded on February 28, 1997 by Peter G. Milner and Pascal Druzgala and is headquartered in Fremont, CA. |
| URL | http://www.aryx.com |
| Investor Relations URL | N/A |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | N/A |
| Last Earnings Release | Mar. 28, 2011 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| ARYx Therapeutics, Inc. discovers and develops drugs for large, chronic disease markets. Its products include Naronapride, a proprietary serotonin type 4 (5HT4) for the treatment of multiple gastrointestinal disorders, Budiodarone, a proprietary compound in Phase 2 development for the treatment of atrial fibrillation, Tecarfarin, a novel compound for oral anti-coagulation therapy, and ATI-9242, a typical antipsychotic for the treatment of schizophrenia and other psychiatric disorders. The company was founded on February 28, 1997 by Peter G. Milner and Pascal Druzgala and is headquartered in Fremont, CA. |
| URL | http://www.aryx.com |
| Investor Relations URL | N/A |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | N/A |
| Last Earnings Release | Mar. 28, 2011 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |